Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1997-09-19
2000-09-05
Eyler, Yvonne
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
5303881, 4241301, 4241331, 4241451, C07K 1600
Patent
active
061145068
ABSTRACT:
The present invention relates to a novel alpha-2-antiplasmin-binding molecules and treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient which comprises administering an alpha-2-antiplasmin-binding molecule capable of preventing inhibition of plasmin by endogenous alpha-2-antiplasmin. The invention also relates to a treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient comprising coadministrating an alpha-2-antiplasmin-binding molecule of the invention together with a thrombolytic agent.
REFERENCES:
patent: 4147765 (1979-04-01), Stephan et al.
patent: 4198335 (1980-04-01), Collen
patent: 4245040 (1981-01-01), Pigeram
patent: 4273873 (1981-06-01), Sugitachi et al.
patent: 4346029 (1982-08-01), Collen
patent: 4368149 (1983-01-01), Masuho et al.
patent: 4414148 (1983-11-01), Jansen et al.
patent: 4421735 (1983-12-01), Haber et al.
patent: 4455290 (1984-06-01), Olexa et al.
patent: 4470925 (1984-09-01), Auditore-Hargreaves
patent: 4474893 (1984-10-01), Reading
patent: 4545988 (1985-10-01), Nakayama et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4673573 (1987-06-01), Ferres et al.
patent: 4722903 (1988-02-01), Kudryk et al.
patent: 4758524 (1988-07-01), Bundesen et al.
patent: 4833085 (1989-05-01), Schaumann et al.
patent: 4916070 (1990-04-01), Matsueda et al.
patent: 4927916 (1990-05-01), Matsueda et al.
patent: 5116613 (1992-05-01), Haber et al.
patent: 5372812 (1994-12-01), Reed et al.
patent: 5582862 (1996-12-01), Reed et al.
patent: 5585089 (1996-12-01), Queen et al.
Butte, A.N. et al., ".alpha..sub.2 -Antiplasmin Causes Thrombi to Resist Fibrinolysis Induced by Tissue Plasminogen Activator in Experimental Pulmonary Embolism," Circulation 95:1886-1891 (Apr. 1997).
Jones, P.T. et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," Nature 321:522-525 (1986).
Reed, G.L., "Functional Characterization of Monoclonal Antibody Inhibitors of .alpha.2-Antiplasmin that Accelerate Fibrinolysis in Different Animal Plasmas," Hybridoma 16:281-286 (Jun. 1997).
Reed, G.L., "Monoclonal Antibodies: 77 (anti .alpha.22 antiplasmin)," Hybridoma 16:392 (Aug. 1997).
Sakata, Y. et al., "Clot Lysis Induced by a Monoclonal Antibody Against .alpha..sub.2 -Plasmin Inhibitor," Blood 74:2692-2697 (1989).
Soe, G. et al., "A rapid latex immunoassay for the detection of plasmin-.alpha..sub.2 -plasmin inhibitor complex. Utilization of two monoclonal antibodies differentially recognizing respective components of the complex," Blood Coagulation & Fibrinolysis 6:249-258 (May 1995).
Agnelli, G. et al., "The Comparative Effects of Recombinant Hirudin (CGP 39393) and Standard Heparin on Thrombus Growth in Rabbits," Thrombosis and Hemostasis 63 (2):204-207 (1990).
Agnelli, G. et al., "A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits," Circulation 72(1):178-182 (1985).
Agnelli, G. et al., "Sustained Thrombolysis With DNA-Recombinant Tissue Type Plasminogen Activator in Rabbits," Blood 66 (2):399-401 (1985).
Angles-Cano, E. R., "Tissue plasminogen activator determination with a fibrin-supported film," Chem. Abstracts 104:307-308, Abstract No. 144639d (1986).
Aoki, N. et al., "Fibrin-Associated Plasminogen Activation in .alpha..sub.2 -Plasmin Inhibotor Deficiency," Blood 62(5):1118-1122 (1983).
Bates, E. R. et al., "A Monoclonal Antibody Against the Platelet Glycoprotein IIb/IIIa Receptor Complex Prevents Platelet Aggregation and Thrombosis in a Canine Model of Coronary Angioplasty," Circulation 84 (6):2463-2469 (1991).
Bode, C. et al., "Conjugation to Antifibrin Fab' Enhances Fibrinolytic Potency of Single-Chain Urokinase Plasminogen Activator," Circulation 81(6):1974-1980 (1990).
Bode, C., et al., "Antibody-Directed Urokinase: A Specific Fibrinolytic Agent," Science 229:765-767 (1985).
Bode, C. et al., "Thrombolysis by a Fibrin-specific Antibody Fab'-Urokinase Conjugate," J. Mol. Cell. Cardiol. 19:335-341 (1987).
Bode, C. et al., "Antibody-directed Fibrinolysis: An Antibody Specific For Both Fibrin and Tissue Plasminogen Activators," J. Biol. Chem. 264(2):944-948 (1989).
Boulianne, G. L. et al., "Production of functional chimaeric mouse/human antibody," Nature 312:643-646 (1984).
Branscomb, E. E. et al., "Bispecific Monoclonal Antibodies Produced by Somatic Cell Fusion Increase the Potency of Tissue Plasminogen Activator," Thrombosis and Haemostasis 64(2):260-266 (1990).
Brennan, M. et al., "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G.sub.1 Fragments," Science 229:81-83 (1985).
Carrasquillo, J. A. et al., "Radioimmunodetection of Human Melanoma with Monoclonal Antibodies and Fab Fragments," in: Radioimmunoimaging and Radioimmunotherapy, Burchiel, S. and B. Rhodes, Eds, Elsevier Science Publishing Co., Inc.; Amsterdam, pp. 357-368 (1983).
Charpie, J. R. et al., "A Bispecific Antibody Enhances the Fibrinolytic Potency of Single-Chain Urokinase," Biochemistry 29(27):6374-6378 (1990).
Collen, D. et al., "Thrombolysis with Human Extrinsic (Tissue-Type) Plasminogen Activator in Rabbits with Experimental Jugular Vein Thrombosis," J. Clin. Invest. 71:368-376 (1983).
Collen, D. et al., "Thrombolytic and Pharmacokinetic Properties of Chimeric Tissue-Type and Urokinase-Type Plasminogen Activators," Circulation 84(3):1216-1234 (1991).
Collen, D. et al., "Synergism of thrombolytic agents in vivo," Circulation 74(4):838-842 (1986).
DeWood, M. A. et al., "Prevalence of Total Coronary Occlusion During the Early Hours of Transmural Myocardial Infarction," New England J. Med. 303(16):897-902 (1980).
Dorai, H. and G. P. Moore, "The Effect of Dihydrofolate Reductase-Mediated Gene Amplification on the Expression of Transfected Immunoglobulin Genes," J. Immunol. 139(12):4232-4241 (1987).
Duberstein, R., "Scientists Develop New Technique for Producing Bispecific Monoclonals," Genetic Engineering News 6:22-24 (1986).
Emeis, J. J. and J. H. Verheijen, "Thrombolytic Properties in a Rabbit Jugular Vein Thrombosis Model of a Tissue-type Plasminogen Activator Mutant Lacking the Growth Factor- and Kringle One-Domains," Arzneim.-Forsch./Drug Res. 42(3):358-362 (1992).
Fisher, R. et al., "Isolation and Characterization of the Human Tissue-type Plasminogen Activator Structural Gene Including Its 5' Flanking Region," J. Biol. Chem. 260(20):11223-11230 (1985).
Gardell, S. J. et al., "Effective Thrombolysis Without Marked Plasminemia After Bolus Intravenous Administration of Vampire Bat Salivary Plasminogen Activator in Rabbits," Circulation 84(1):244-253 (1991).
Gold, H. K. et al., "Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion," Circulation 73(2):347-352 (1986).
Harris, W.J. and S. Emery, "Therapeutic Antibodies--The Coming of Age," T. Biotech. 111:42-44 (1993).
Hattey, E. et al., "Monoclonal Antibodies Against Plasminogen and Alpha-2-Antiplasmin: Binding to Native and Modified Antigens," Thrombosis Res. 45:485-495 (1987).
Hessel, B. et al., "Primary Structure of Human Fibrinogen and Fibrin: Structural Studies on NH.sub.2 -terminal Part of B.beta. Chain," Eur. J. Biochem. 98:521-534 (1979).
Houranieh, A. et al., "Monoclonal Antibodies to Human Cross-Linked Fibrin," Fed. Proc. 44:1846, Abstract No. 8381 (1985).
Hui, K. Y. et al., "Immunodetection of Human Fibrin Using Monoclonal Antibody-64C5 in an Extracorporeal Chicken Model," Thrombosis and Haemostasis 54(2):524-527 (1985).
Hui, K. Y. et al., "Monoclonal Antibodies of Predetermined Specificity for Fibrin: A Rational Approach to Monoclonal Antibody Research," Hybridoma 5(3):215-222 (1986).
Hui, K. Y. et al., "Monoclonal Antibodies to a Synthetic Fibrin-Like Peptide Bind to Human Fibrin but not Fibrinogen," Science 222:1129-1132 (1983).
Ito, R. K. et al., "Fibrinolysis Studies: Fibrinogen-Specific Antibody as Carriers for Fibrinolytic Agents," Fed. Proc. 44:1846, Abstract No. 8382 (1985).
Kabnick, K. S. and D. E. Housman, "Determinants That Contribute
Bajorath Jurgen
Harris Linda
Hsu Mei-Yin
Matsueda Gary
Novotny Jiri
Bristol--Myers Squibb Company
Davis Minh-Tam
Eyler Yvonne
General Hospital Corporation
President and Fellows of Harvard College
LandOfFree
Composition and method for enhancing fibrinolysis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for enhancing fibrinolysis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for enhancing fibrinolysis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2213396